Literature DB >> 12721773

Drug formulations intended for the global market should be tested for stability under tropical climatic conditions.

P G Risha1, C Vervaet, G Vergote, L Van Bortel, J P Remon.   

Abstract

RATIONALE
OBJECTIVE: The quality of drugs imported into developing countries having a tropical climate may be adversely affected if their formulations have not been optimized for stability under these conditions. The present study investigated the influence of tropical climate conditions (class IV: 40 degrees C, 75% relative humidity) on the drug content, in vitro dissolution and oral bioavailability of different formulations of two essential drugs marketed in Tanzania: diclofenac sodium and ciprofloxacin tablets.
METHODS: Before and after 3 and 6 months storage under class IV conditions the drug content and in vitro dissolution were evaluated using United States Pharmacopoeia (USP) 24 methods. Following a randomized four-period cross-over study, the pharmacokinetic parameters of drug formulations stored for 3 months under class IV conditions were compared with those stored at ambient conditions.
RESULTS: Drug content and drug release from all tested ciprofloxacin formulations were within USP-24 requirements and remained stable during storage at simulated tropical conditions. Oral bioavailability was also not influenced by tropical conditions. The dissolution rate of two diclofenac formulations (Diclo 50 manufactured by Camden and Dicloflame 50 manufactured by Intas) reduced significantly during storage under class IV conditions. After oral administration Camden tablets stored for 3 months under class IV conditions showed a reduction in C(max) (90% CI of C(max) ratio: 0.59 - 0.76). This reduction was smaller than expected based on the in vitro tests.
CONCLUSIONS: Some drug formulations imported into Tanzania are not optimized for stability in a tropical climate. Manufacturers and regulatory authorities should pay more attention to the WHO recommendations for testing the stability of drugs under tropical climate conditions. Efforts should be made to improve the in vitro tests to better predict the bioavailability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721773     DOI: 10.1007/s00228-003-0587-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Regulatory aspects of stability testing in Europe.

Authors:  B R Matthews
Journal:  Drug Dev Ind Pharm       Date:  1999-07       Impact factor: 3.225

2.  Influence of storage on in-vitro release of ibuprofen from sugar coated tablets.

Authors:  D J Saville
Journal:  Int J Pharm       Date:  2001-08-14       Impact factor: 5.875

3.  Evaluation of USP apparatus 3 for dissolution testing of immediate-release products.

Authors:  Lawrence X Yu; Jin T Wang; Ajaz S Hussain
Journal:  AAPS PharmSci       Date:  2002

4.  Bioavailability of a new effervescent tablet of diclofenac.

Authors:  B Terhaag; A Hoffmann; M Barkworth; B Vens-Cappell
Journal:  Int J Clin Pharmacol Ther       Date:  2000-11       Impact factor: 1.366

5.  In vitro evaluation of the quality of essential drugs on the Tanzanian market.

Authors:  Peter G Risha; Danstan Shewiyo; Amani Msami; Gerald Masuki; Geert Vergote; Chris Vervaet; Jean Paul Remon
Journal:  Trop Med Int Health       Date:  2002-08       Impact factor: 2.622

6.  Effect of aging on the dissolution stability of glibenclamide/beta-cyclodextrin complex.

Authors:  R J Babu; J K Pandit
Journal:  Drug Dev Ind Pharm       Date:  1999-11       Impact factor: 3.225

7.  Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.

Authors:  L Endrenyi; S Fritsch; W Yan
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-10

8.  An alternative high-performance liquid chromatographic method for the determination of diclofenac and flurbiprofen in plasma.

Authors:  G Giagoudakis; S L Markantonis
Journal:  J Pharm Biomed Anal       Date:  1998-08       Impact factor: 3.935

Review 9.  Current perspectives on the dissolution stability of solid oral dosage forms.

Authors:  K S Murthy; I Ghebre-Sellassie
Journal:  J Pharm Sci       Date:  1993-02       Impact factor: 3.534

10.  Tear concentrations of topically applied ciprofloxacin.

Authors:  M Limberg; C Buggé
Journal:  Cornea       Date:  1994-11       Impact factor: 2.651

View more
  6 in total

1.  The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing.

Authors:  Mubarak Nasser Al Ameri; Nanda Nayuni; K G Anil Kumar; David Perrett; Arthur Tucker; Atholl Johnston
Journal:  Results Pharma Sci       Date:  2011-12-07

2.  Keep in a cool place: exposure of medicines to high temperatures in general practice during a British heatwave.

Authors:  Brian Crichton
Journal:  J R Soc Med       Date:  2004-07       Impact factor: 18.000

3.  The Quality of Selected Essential Medicines Sold in Accredited Drug Dispensing Outlets and Pharmacies in Tanzania.

Authors:  Eliangiringa Kaale; Vicky Manyanga; Mhina Chambuso; Jafary Liana; Edmund Rutta; Martha Embrey; Thomas Layloff; Keith Johnson
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

4.  Thermo-, Radio- and Photostability of Perindopril Tert-butyloamine in The Solid State. Comparison to Other Angiotensin Converting Enzyme Inhibitors.

Authors:  Anna Wzgarda; Katarzyna Dettlaff; Martyna Rostalska; Ewa Pabian; Katarzyna Regulska; Beata Jadwiga Stanisz
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

5.  In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia.

Authors:  Solomon Hambisa; Sileshi Belew; Sultan Suleman
Journal:  Drug Des Devel Ther       Date:  2019-04-17       Impact factor: 4.162

6.  Terahertz pulsed imaging and magnetic resonance imaging as tools to probe formulation stability.

Authors:  Qilei Zhang; Lynn F Gladden; Paolo Avalle; J Axel Zeitler; Michael D Mantle
Journal:  Pharmaceutics       Date:  2013-10-25       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.